GlassScriptPhysician profile
Michelle L Sidor
NPI 1821549437
$2,565.11
in general payments reported to CMS, 2019-2025
22 companies · $360 in 2025
The $360 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $873 · 2022: $503 · 2023: $560 · 2024: $270 · 2025: $360.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $924 · Consulting Fee: $200 · Education: $65.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $923.56 |
| Consulting Fee | $200.00 |
| Education | $65.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $560.37 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $355.10 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $294.53 | 2021-2023 | Glassia |
| Welch Allyn | $164.92 | 2021 | |
| Novo Nordisk INC | $147.16 | 2021-2025 | Rybelsus |
| Glaxosmithkline, LLC. | $145.24 | 2021-2024 | Shingrix, Arexvy |
| Astellas Pharma US INC | $134.02 | 2021-2023 | Veozah, Myrbetriq |
| Lilly USA, LLC | $121.24 | 2021-2025 | Mounjaro |
| Pfizer INC. | $99.21 | 2021-2025 | |
| Genzyme Corporation | $91.66 | 2021-2022 | |
| Abbvie INC. | $75.16 | 2021-2024 | |
| Amgen INC. | $65.04 | 2023-2025 | Repatha, Otezla, Repatha |
| Eisai INC. | $55.59 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.05 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $42.39 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $39.11 | 2023 | |
| Amarin Pharma, INC. | $38.88 | 2021-2022 | |
| Inspire Medical Systems, INC. | $24.76 | 2024 | Inspire |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.89 | 2021 | |
| Exact Sciences Corporation | $16.37 | 2024 | Cologuard Collection Kit |
| Sunovion Pharmaceuticals INC. | $16.09 | 2021 | |
| Idorsia Pharmaceuticals US INC | $13.33 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Sidor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.